[go: up one dir, main page]

BR0015170A - Hcv proteins with reversible redox and conformation similar to native - Google Patents

Hcv proteins with reversible redox and conformation similar to native

Info

Publication number
BR0015170A
BR0015170A BR0015170-0A BR0015170A BR0015170A BR 0015170 A BR0015170 A BR 0015170A BR 0015170 A BR0015170 A BR 0015170A BR 0015170 A BR0015170 A BR 0015170A
Authority
BR
Brazil
Prior art keywords
hcv proteins
native
conformation similar
reversible redox
relates
Prior art date
Application number
BR0015170-0A
Other languages
Portuguese (pt)
Inventor
Alfons Bosman
Erick Depla
Geert Maertens
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR0015170A publication Critical patent/BR0015170A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PROTEìNAS DE HCV COM OXIRREDUçãO REVERSìVEL E CONFORMAçãO SIMILAR à NATIVA". A presente invenção refere-se a proteínas de HCV nas quais os resíduos de cisteína são protegidos reversivelmente durante a purificação. Eventualmente, este procedimento de purificação resulta em proteínas de HCV com atividade biológica e uma conformação similar à nativa, que apresentam epítopos correspondentes. A presente invenção refere-se também a métodos de triagem de fármacos, usando essas proteínas de HCV, e aplicações diagnósticas e terapêuticas, tais como vacinas e medicamentos."HCV PROTEINS WITH REVERSIBLE OXYREDUCTION AND CONFORMATION SIMILAR TO NATIVE". The present invention relates to HCV proteins in which the cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a conformation similar to the native one, which have corresponding epitopes. The present invention also relates to methods of drug screening, using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and medications.

BR0015170-0A 1999-10-27 2000-10-25 Hcv proteins with reversible redox and conformation similar to native BR0015170A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99870225 1999-10-27
US16928899P 1999-12-07 1999-12-07
PCT/EP2000/010499 WO2001030815A1 (en) 1999-10-27 2000-10-25 Redox reversible hcv proteins with native-like conformation

Publications (1)

Publication Number Publication Date
BR0015170A true BR0015170A (en) 2002-06-25

Family

ID=30129297

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015170-0A BR0015170A (en) 1999-10-27 2000-10-25 Hcv proteins with reversible redox and conformation similar to native

Country Status (14)

Country Link
EP (1) EP1224214A1 (en)
JP (1) JP2003513022A (en)
CN (1) CN1384839A (en)
AU (1) AU1144501A (en)
BR (1) BR0015170A (en)
CA (1) CA2387666A1 (en)
CZ (1) CZ20021819A3 (en)
HU (1) HUP0203195A3 (en)
MX (1) MXPA02004052A (en)
NZ (1) NZ518095A (en)
PL (1) PL354990A1 (en)
RU (1) RU2002109480A (en)
WO (1) WO2001030815A1 (en)
ZA (1) ZA200203169B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064835A1 (en) 2000-07-10 2002-05-30 Diosynth Rtp, Inc. Purification of human troponin I
RU2274643C2 (en) 2001-04-24 2006-04-20 Иннодженетикс Н.В. Isolated envelope hcv protein, method for its preparing and drug, vaccine, pharmaceutical composition (variants) comprising thereof
EP1481984A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS5
BR112015023355A8 (en) * 2013-03-14 2018-01-30 Abbott Lab hcv ns3 recombinant antigens and mutants thereof for enhanced antibody detection.
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
KR960013600B1 (en) * 1989-06-02 1996-10-09 제네틱 시스팀스 코포레이션 Cysteine Thiol-Protecting Peptides Used in Immunoassay
ES2174957T5 (en) * 1994-07-29 2006-12-16 Innogenetics N.V. PURIFIED PROTEINS OF HEPATITIS C VIRUS WRAPPING FOR DIAGNOSTIC AND THERAPEUTIC USE.
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue

Also Published As

Publication number Publication date
HUP0203195A3 (en) 2004-07-28
RU2002109480A (en) 2004-03-10
MXPA02004052A (en) 2002-11-07
AU1144501A (en) 2001-05-08
HUP0203195A2 (en) 2002-12-28
ZA200203169B (en) 2003-09-23
WO2001030815A1 (en) 2001-05-03
JP2003513022A (en) 2003-04-08
CA2387666A1 (en) 2001-05-03
PL354990A1 (en) 2004-03-22
CZ20021819A3 (en) 2003-06-18
NZ518095A (en) 2003-09-26
EP1224214A1 (en) 2002-07-24
CN1384839A (en) 2002-12-11

Similar Documents

Publication Publication Date Title
Marrero et al. The crystal structure of human α2‐macroglobulin reveals a unique molecular cage
Marcinkiewicz et al. EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner
IL233223A (en) Pharmaceuticals and diagnostic preparations containing nucleic acids and corresponding proteins known as p1g3282
CY1120558T1 (en) AN RDEN3 / 4DELTA 30 (ME), RDEN2 / 4DELTA30 (ME) OR RDEN1 / 4DELTA30 (ME) ANASYNDYASMENOS CHIMAIRIKOS IOS dengue WHO CONTAINING AN 30 NUCLEOTIDE DELETION (DELTA30) in a portion of the 3 'AMETAFRASTIS REGION OF GENOMIC virus DIAGNOSIS OF TYPE 4, WHICH HAS ABOUT 30 NUCLEAR DIPLOMATS MATCHES TO TL2 STRUCTURE-LOOSE STRUCTURE
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
DE60032486D1 (en) PRION PROTEIN PEPTIDES AND ITS USE
BR9909860A (en) Specific cd19xcd3 polypeptides and their uses
ATE389724T1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
BR0211623A (en) Peptide-based multimeric target contrast agents
BR9814276A (en) Surface antigens
DE60135498D1 (en) Production of Whole Antibodies in Prokaryotic Cells
BR0112540A (en) Peptides as Hepatitis C Virus Ns-3-Serine Protease Inhibitors
DK0750672T3 (en) DNA sequences for matrix metal proteases, their generation and use
BR9809445A (en) Polypeptide comprising an immunogenic portion of a m antigen. tubercolosis, dna molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, processes for inducing protective immunity in a patient, tuberculosis detection process in a patient, and, diagnostic kit.
ATE354638T1 (en) HUMAN TISSUE INHIBITOR OF METALLOPROTEINASE-4
DE69130071D1 (en) COMPOSITION USED AS A THERAPEUTIC AGENT AGAINST CHRONIC VIRAL LIVER DISEASES
ATE293169T1 (en) LATENCY ASSOCIATED PEPTIDES OF TGF-BETA TO MAKE PHARMACEUTICALLY ACTIVE PROTEINS LATENCY
BR0015170A (en) Hcv proteins with reversible redox and conformation similar to native
DE60335549D1 (en) Recovery of heat shock proteins
EP1663201A4 (en) USE OF NEW 2-OXO-HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
DE50212280D1 (en) USE OF HMGB PROTEINS AND NUCLEIC ACIDS COORDINATING THEREOF
ATE554793T1 (en) CONJUGATE
BRPI0413944A (en) isolated nucleic acid molecules of s. mansoni and use of these
ID23184A (en) SALES OF BPC PEPTIDES WITH ORGANOPROTECTIVE ACTIVITIES FOR THE PROCESS OF MAKING AND USING IT IN THERAPY
BR9814433A (en) "beta-lipotropin and its uses"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.